CHEMOTHERAPY AND VENETOCLAX IN ELDERLY AML TRIAL (CAVEAT): A PHASE 1B DOSE ESCALATION STUDY EXAMINING MODIFIED INTENSIVE CHEMOTHERAPY IN FIT ELDERLY PATIENTS
EHA Learning Center, Andrew Wei, 214491
TP53 MUTATION HAD A NEGATIVE PROGNOSTIC IMPACT IN UNTREATED YOUNG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AT HIGH-RISK: A SUB-ANALYSIS OF FIL-DLCL04 STUDY
EHA Learning Center, Annalisa Chiappella, 214569
GENOMIC ALTERATIONS IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA FREQUENTLY AFFECT CELL CYCLE KEY REGULATORS AND NOTCH1 REGULATED TRANSCRIPTION.
EHA Learning Center, Jennifer Edelmann, 214583
THE FREQUENCY OF THE ETHNIC NEUTROPENIA-ASSOCIATED RS2814778 SNP OF DUFFY ANTIGEN RECEPTOR FOR CHEMOKINES (DARC) GENE IN A COHORT OF EUROPEAN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA
EHA Learning Center, Helen Papadaki, 214588
NOVEL INSIGHTS INTO SPLEEN INJURY DURING THE FIRST 2 YEARS OF LIFE IN SCA CHILDREN: A LONGITUDINAL STUDY
EHA Learning Center, Sara El Hoss, 214590
SINGLE-CELL PROFILING REVEALS KEY DIFFERENCES IN THE CELLULAR ARCHITECTURE OF HUMAN HAEMATOPOIETIC STEM AND PROGENITOR CELLS THROUGHOUT FETAL AND ADULT LIFE
EHA Learning Center, Anindita Roy, 214591
THE MUTATIONAL LANDSCAPE IN HYDROXYCARBAMIDE-RESISTANT/INTOLERANT ESSENTIAL THROMBOCYTHEMIA TREATED ON THE MAJIC-ET STUDY
EHA Learning Center, Jennifer O'Sullivan, 214619
PRECLINICAL EVALUATION OF THE NEW BCMAXCD3 BISPECIFIC ANTIBODY JNJ-957 FOR THE TREATMENT OF MULTIPLE MYELOMA
EHA Learning Center, Kristine Frerichs, 214621
PHASE 1B/2 COMBINATION STUDY OF APR-246 AND AZACITIDINE (AZA) IN PATIENTS WITH TP53 MUTANT MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, David Sallman, 214477
DURABLE RESPONSE WITH VENETOCLAX IN COMBINATION WITH DECITABINE OR AZACITADINE IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Courtney D. DiNardo, 214482
PERSISTENT BCR-ABL1 CLONAL HEMATOPOIESIS AFTER BLAST CLEARANCE IDENTIFIES A CML-LIKE SUBGROUP OF PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ALL: INTERIM RESULTS FROM THE GRAAPH-2014 TRIAL
EHA Learning Center, Emmanuelle Clappier, 214483
FAVOURABLE OUTCOMES WITH R-CODOX-M/R-IVAC ACROSS ALL SUBGROUPS OF AGGRESSIVE HIGH GRADE B-CELL LYMPHOMA: PATHOLOGY AND UPDATED SURVIVAL RESULTS FROM A PHASE 2 UK NCRI/LLR TRIAL
EHA Learning Center, Elizabeth Phillips, 214487
SIMULTANEOUS TARGETING OF MCL-1 (S63845) AND BCL-2 (VENETOCLAX) ANTI-APOPTOTIC PROTEINS IN MULTIPLE MYELOMA
EHA Learning Center, Esperanza Macarena Algarin, 214498
PERIVASCULAR NICHE CELLS SENSE THROMBOCYTOPENIA AND ACTIVATE PLATELET-BIASED HSCS IN AN IL-1 DEPENDENT MANNER
EHA Learning Center, Tiago Cunha Luis, 214499
THE COMBINATION OF THE MDM2 ANTAGONIST, IDASANUTLIN WITH NILOTINIB TARGETS PRIMITIVE CHRONIC MYELOID LEUKEMIA (CML) CELLS IN VITRO AND IN VIVO.
EHA Learning Center, Mary Scott, 214573
GROWTH DYNAMICS IN NATURALLY PROGRESSING CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Michaela Gruber, 214582
PROGNOSTIC FACTORS FOR HLH IN ADULTS – ANALYSIS FROM THE PALG HLH IN ADULTS DATABASE
EHA Learning Center, Rafal Machowicz, 214623
GENOME WIDE ASSOCIATION STUDIES (GWAS) OF CEREBROVASCULAR EVENTS IN PATIENTS WITH SICKLE CELL ANAEMIA (SCA)
EHA Learning Center, John Brewin, 214626
IMETELSTAT IN RBC TRANSFUSION-DEPENDENT (TD) LOWER RISK MDS RELAPSED/REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESA) (IMERGE): UPDATED EFFICACY AND SAFETY
EHA Learning Center, Pierre Fenaux, 214476
MUTANT IDH (MIDH) INHIBITORS, IVOSIDENIB OR ENASIDENIB, WITH AZACITIDINE (AZA) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Courtney D. DiNardo, 214481
MS4A3 REGULATES CELL SURFACE CYTOKINE RECEPTOR EXPRESSION, DIFFERENTIATION, AND DRUG RESISTANCE IN CHRONIC MYELOID LEUKEMIA
EHA Learning Center, Anna Eiring, 214572
GENOME-WIDE ASSOCIATION STUDY REVEALS ANKYRIN REPEAT AND SOCS BOX PROTEIN 3 (ASB3) AND INOSITOL POLYPHOSPHATE MULTIKINASE (IPMK) AS NEW RISK LOCI FOR RELAPSE IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Laura Hinze, 214578
EFFECTS OF DARATUMUMAB ON THE COMPOSITION AND ACTIVATION STATUS OF IMMUNE-CELL POPULATIONS IN CENTAURUS, A PHASE 2 RANDOMIZED STUDY OF SMOLDERING MULTIPLE MYELOMA (SMM) PATIENTS
EHA Learning Center, Homer Adams III, 214585
MANAGEMENT OF ELANE-NEUTROPENIA: LIFETIME G-CSF VS HAEMATOPOIETIC STEM CELL TRANSPLANTATION LEARNING LESSON FROM THE EXPERIENCE
EHA Learning Center, Francesca Fioredda, 214587
1 INTRAVASCULAR HEMOLYSIS INDUCES COMPLEMENT SYSTEM ACTIVATION MEDIATED BY HEME AND HEME-LOADED ERYTHROCYTE MICROVESICLES
EHA Learning Center, Lubka Roumenina, 214589
IMPACT OF CONCURRENT FOLLICULAR LYMPHOMA OR OTHER LOW-GRADE B-CELL LYMPHOMA ON THE CLINICAL OUTCOME OF DIFFUSE LARGE B-CELL LYMPHOMA
EHA Learning Center, Yucai Wang, 214618
OVEREXPRESSION OF THE TRANSCRIPTION FACTOR CDX2 IN HAEMATOPOIETIC STEM CELLS PREDISPOSES TO HAEMATOLOGICAL MALIGNANCIES
EHA Learning Center, Therese Vu, 214629
INTEGRATED ATAC-SEQ AND SINGLE-CELL SYNERGISTIC CHEMOSENSITIVITY PROFILING IDENTIFIES RATIONAL DRUG COMBINATIONS IN IBRUTINIB-TREATED CLL PATIENTS
EHA Learning Center, Gregory Vladimer, 214638
ENASIDENIB MONOTHERAPY IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH PREVIOUSLY UNTREATED MUTANT-IDH2 (MIDH2) ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Daniel A. Pollyea, 214480
SURVIVAL OF VERY ELDERLY PATIENTS WITH DLBCL ACCORDING TO TREATMENT INTENSITY IN THE RITUXIMAB ERA: A SWEDISH LYMPHOMA REGISTRY STUDY
EHA Learning Center, Kristina Sonnevi, 214568
JAK1-STAT3 SIGNALING AXIS SUPPORTS LEUKEMIC STEM CELL PERSISTENCE IN CML
EHA Learning Center, Mirle Schemionek, 214571
A RANDOMIZED PHASE II STUDY OF STANDARD DOSE AZACITIDINE ALONE OR IN COMBINATION WITH LENALIDOMIDE IN HIGH-RISK MDS WITH A KARYOTYPE INCLUDING DEL(5Q)
EHA Learning Center, Bengt Rasmussen, 214575
A NOVEL, INTEGRATED AND VALIDATED PROGNOSTIC INDEX FOR PREDICTING OUTCOME IN ACUTE LYMPHOBLASTIC LEUKAEMIA PROVIDES NEW APPROACH FOR RISK STRATIFICATION.
EHA Learning Center, Anthony Moorman, 214577
CLINICAL IMPORTANCE OF DNA METHYLATION SIGNATURES IN CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS TREATED WITH CHEMO-IMMUNOTHERAPY
EHA Learning Center, J.C. Strefford, 214580
EXPRESSION OF PROTEINS IN CD138+ PLASMA CELLS PREDICTS PROGNOSIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH VRD REGIMEN.
EHA Learning Center, Irena Misiewicz-Krzeminska, 214584
CHARACTERIZATION OF ORALLY BIOAVAILABLE SMALL MOLECULE INHIBITORS OF COMPLEMENT C5
EHA Learning Center, Alonso Ricardo, 214586
THE EFFECT OF COMPLEMENT INHIBITOR CP40 ON ERYTHROCYTE DESTRUCTION IN AIHA
EHA Learning Center, Inge Baas, 214625
P53 DEFICIENCY DRIVES LEUKEMIC TRANSFORMATION OF HEMATOPOIETIC STEM CELLS BY MAINTAINING QUIESCENCE IN RESPONSE TO DNA DAMAGE
EHA Learning Center, Andreas Brown, 214628
IVOSIDENIB (AG-120) IN MUTANT IDH1 RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS OF A PHASE 1 STUDY
EHA Learning Center, Daniel A. Pollyea, 214479
RADIOTHERAPY TO BULKY AND EXTRALYMPHATIC DISEASE IN COMBINATION WITH 6XR-CHOP-14 OR R-CHOP-21 IN YOUNG GOOD-PROGNOSIS DLBCL PATIENTS: RESULTS OF THE 2X2 RANDOMIZED UNFOLDER TRIAL OF THE DSHNHL/GLA
EHA Learning Center, Michael Pfreundschuh, 214567
THE TUMOR SUPPRESSOR MIR-300 PRESERVES CANCER STEM CELLS AND INHIBITS NK CELL ANTICANCER IMMUNITY
EHA Learning Center, Danilo Perrotti, 214570
A PHASE II CLINICAL TRIAL OF GUADECITABINE (SGI-110) FOR PATIENTS WITH PREVIOUSLY UNTREATED MYELODYSPLASTIC SYNDROME
EHA Learning Center, Guillermo Garcia-Manero, 214574
OUTCOMES OF YOUNG ADULT (≥ 18-25 YEARS) AND PEDIATRIC (<18 YEARS) PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA FOLLOWING TREATMENT WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY
EHA Learning Center, Susana Rives, 214576
LINKING ABERRANT CHROMATIN FEATURES IN CHRONIC LYMPHOCYTIC LEUKEMIA TO DEREGULATED TRANSCRIPTION FACTOR NETWORKS
EHA Learning Center, Viola Meyer-Pannwitt, 214579
THE CHRONOLOGICAL ORDER OF COPY NUMBER CHANGES IN HYPERDIPLOID MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Francesco Maura, 214620
A COHORT OF 22 PATIENTS WITH SAMD9/SAMD9L DISORDER: BONE MARROW FAILURE AND MDS PREDISPOSITION WITH TRANSIENT MONOSOMY 7
EHA Learning Center, Marie Sébert, 214622
RED CELL EFFECTS OF THE ANTI-CD47 MONOCLONAL ANTIBODY HU5F9-G4 IN A PHASE I STUDY FOR RELAPSED OR PRIMARY REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Learning Center, Charlotte Brierley, 214624
SPECIFICATION OF HEMATOPOIETIC STEM CELL FATE VIA MODULATION OF MITOCHONDRIAL ACTIVITY
EHA Learning Center, Mukul Girotra, 214627
INTEGRATED EXPRESSION PROFILING CHARACTERIZES BIOLOGICAL HETEROGENEITY IN REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND THE RISK OF RICHTER TRANSFORMATION
EHA Learning Center, Johannes Bloehdorn, 214581
SINGLE-CELL DNA ANALYSIS OF MUTATIONAL HETEROGENEITY IN ACUTE MYELOID LEUKEMIA TUMORS WITH HIGH-THROUGHPUT DROPLET MICROFLUIDICS
EHA Learning Center, Dennis Eastburn, 214633
CANDIDATE FDA-APPROVED DRUGS THAT MAY MIMIC HOXA CLUSTER DELETION IN MLL-AF9 LEUKEMIA.
EHA Learning Center, Laura Kettyle, 214634
MUTATIONAL LANDSCAPE OF RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA
EHA Learning Center, Valentina Alfonso, 214635
THE ROLE OF THE TRANSCRIPTION FACTOR GFI1 IN LEUKEMIA GENOME STABILITY AND EVOLUTION
EHA Learning Center, Daria Frank, 214636
VEGFC ANTIBODY TREATMENT: A NEW DIFFERENTIATION THERAPY FOR AML
EHA Learning Center, Kim Kampen, 214637
GENE EXPRESSION PROFILING IDENTIFIES CHARACTERISTIC TRANSCRIPTIONAL SIGNATURES OF GENOMIC INSTABILITY IRRESPECTIVE OF TP53 IMPAIRMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Johannes Bloehdorn, 214639
MASS CYTOMETRY REVEALED LEUKEMIC MICROENVIRONMENT COMPLEXITY: IMPLICATIONS FOR IMMUNOTHERAPY IN A MOUSE MODEL OF CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Marina Wierz, 214640
FIRST-IN-CLASS ORAL TYROSINE KINASE INHIBITOR (KAN0439834) TARGETING ROR1 INDUCED SIGNIFICANT APOPTOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
EHA Learning Center, Mohammad Hojjat-Farsangi, 214641
GENOMIC AND CLINICAL CHARACTERIZATION OF THE ROLE OF MYD88 MUTATION STATUS IN WALDENSTROM’S MACROGLOBULINEMIA
EHA Learning Center, Zachary Hunter, 214642
IN-SILICO DISSECTION OF DIFFUSE LARGE B CELL LYMPHOMA MICROENVIRONMENT PROVIDES A 45-GENE PANEL FOR RISK STRATIFICATION
EHA Learning Center, Sabino Ciavarella, 214643
GENOMIC CHARACTERISATION OF CIRCULATING TUMOUR DNA (CTDNA) PREFERENTIALLY IDENTIFIES EARLY CLINICALLY RELEVANT GENOMIC EVENTS AND PROVIDES INSIGHT INTO THE CLONAL ARCHITECTURE OF LYMPHOID MALIGNANCY
EHA Learning Center, Piers Blombery, 214644
THE DIALOG BETWEEN MANTLE CELL LYMPHOMA AND MONOCYTES/MACROPHAGES CAN BE DISRUPTED BY BTK INHIBITION AND MONITORED THROUGH CD163 MODULATION IN VIVO
EHA Learning Center, Antonin Papin, 214645
MYD88 CONSTITUTIVE ACTIVATION IS DIRECTLY ABLE TO INDUCE INDOLENT LYMPHOPLASMACYTIC LYMPHOMA WITH MONOCLONAL IGM PEAK SECRETION IN 1 YEAR OLD MICE: A MODEL FOR WALDENSTROM'S MACROGLOBULINEMIA
EHA Learning Center, Christelle Vincent-Fabert, 214646
CELL OF ORIGIN AND GENOMIC PROFILE OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA DETERMINED USING THE NANOSTRING LST ASSAY AND ULTRA DEEP TARGETED NEXT GENERATION SEQUENCING
EHA Learning Center, Csaba Bödör, 214647
IMPACT OF NPM1 MRD STATUS AFTER TWO CYCLES OF INTENSIVE CHEMOTHERAPY TO INFORM TYPE OF POST-REMISSION THERAPY: A STUDY OF THE AML STUDY GROUP (AMLSG)
EHA Learning Center, Silke Kapp-Schwoerer, 214651
DISTINCT DNA METHYLATION PROFILES IN DIFFERENT CYTOGENETIC SUBGROUPS OF CHRONIC LYMPHOCYTIC LEUKEMIA: THE INTRIGUING CASE OF TRISOMY 12
EHA Learning Center, MARIA TSAGIOPOULOU, 214652
BIALLELIC INACTIVATION OF ATM AND BIRC3 IN DEL(11Q) CELLS DRIVES GENOMIC INSTABILITY AND TUMOR EXPANSION IN CRISPR/CAS9-GENERATED MODELS OF CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Miguel Quijada Alamo, 214653
CD20 IS A DIRECT REGULATOR OF B-CELL RECEPTOR SIGNALING IN THE MICROENVIRONMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Gabriela Pavlasova, 214654
ROLE OF MTORC1 IN NORMAL HAEMOPOIESIS AND LEUKAEMOGENESIS
EHA Learning Center, Natasha Malik, 214655
IDENTIFICATION OF A MIR-146B-FASL AXIS IN THE DEVELOPMENT OF NEUTROPENIA IN T-LARGE GRANULAR LYMPHOCYTES LEUKEMIA
EHA Learning Center, Giulia Calabretto, 214656
INFLAMED BM-MSCS HIGHLY ATTRACT TEL-AML1+ PRE-LEUKEMIC CELLS AND PROVIDE A SUSTAINING NICHE FOR THEIR EMERGENCE
EHA Learning Center, Linda Beneforti, 215233
TRANSLATOME ANALYSIS REVEALS ALTERED SERINE METABOLISM IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Kim Kampen, 215234
TITLE: PROGNOSTIC IMPACT OF THE BCR/ABL1-LIKE SIGNATURE IN ADULT B-LINEAGE ALL. FIRST ANALYSIS OF THE GIMEMA LAL1913 PROTOCOL
EHA Learning Center, Sabina Chiaretti, 215235
CHARACTERIZATION OF PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH DNA METHYLATION STATUS
EHA Learning Center, Shunsuke Kimura, 215236
THE PHILADELPHIA-LIKE SUBTYPE IN CHILDREN WITH FIRST RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: A STUDY OF THE GERMAN ALL-REZ BFM 2002 TRIAL
EHA Learning Center, Malwine Pogodzinski, 215237
HUMAN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA DEVELOPS HYPOXIA-RELATED CHEMORESISTANCE THROUGH HIF1Α AND MTOR PATHWAY INTERACTIONS
EHA Learning Center, Lucine Fahy, 215238
CLONAL EVOLUTION OF ACUTE LYMPHOBLASTIC LEUKEMIA CELLS FROM DIAGNOSIS TO RELAPSE
EHA Learning Center, shumaila sayyab, 215239
REFINED DETECTION AND PHASING OF STRUCTURAL ABERRATIONS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA WITH LINKED-READ WHOLE GENOME SEQUENCING
EHA Learning Center, Yanara Marincevic-Zuniga, 215240
AMPLICON-BASED NGS AS A TOOL FOR THE IDENTIFICATION OF NEW MARKERS WITH POOR PROGNOSIS IN B-ALL
EHA Learning Center, Adrián Montaño, 215241
EXPLORING THE GENOMIC DIVERSITY OF AYA AND ADULT HIGH-RISK B-ALL CASES BY MRNA SEQUENCING
EHA Learning Center, Susan Heatley, 215242
FUNCTIONAL CHARACTERIZATION OF ABERRANT FAT1 EXPRESSION IN T-ALL
EHA Learning Center, Sven Liebig, 215243
“TRIPLE NEGATIVE” ACUTE GENE EXPRESSION CLUSTERING IDENTIFY NEW ADULT LYMPHOBLASTIC LEUKEMIA SUBGROUPS
EHA Learning Center, Anna Ferrari, 215244
MOLECULAR PROFILE REFINES THE MRD-BASED PROGNOSTIC ASSESSMENT IN ADULTS WITH PHILADELPHIA NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Jordi Ribera, 215245
TCR ALPHA GENE REARRANGEMENTS AS A NEW TYPE OF CLONAL MARKERS IN PEDIATRIC T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Alexander Komkov, 215246
COHESIN GENES MUTATIONS IN ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Grazia Fazio, 215248
EVALUATION OF SAMPLE QUALITY AND CREATION OF DATABASES FOR FOLLOW-UP ASSESSMENT OF BLAST INFILTRATION AT DAY +15 IN CHILDHOOD B CELL ACUTE LYMPHOBLASTIC LEUKEMIA.
EHA Learning Center, Pablo Manresa Manresa, 215249
GENETIC ALTERATIONS OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN TAIWAN: A COMPARISON BETWEEN PEDIATRIC AND ADULT COHORTS
EHA Learning Center, Ying-Jung Huang, 215250
FIRST RESULTS OF NEW GIMEMA TRIAL LAL1913 FOR ADULT PATIENTS WITH PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH- ALL)
EHA Learning Center, Renato Bassan, 215251
LOW MIR-151 AND MIR-451 LEVELS IN BONE MARROW AT DIAGNOSIS IS CONFIRMED AS A PROGNOSTIC FACTOR FOR RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM THE AIEOP 2000 CLINICAL TRIAL
EHA Learning Center, Jennifer Yarden, 215252
THE CELL SURFACE PROTEIN VANIN-2 IDENTIFIES AGGRESSIVE SUBTYPES OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Virginia Rodriguez Martinez, 215253
NILOTINIB COMBINED WITH LOWER-INTENSITY CHEMOTHERAPY FOR FRONT-LINE TREATMENT OF YOUNGER ADULTS WITH PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): INTERIM ANALYSIS OF THE GRAAPH-2014 TRIAL
EHA Learning Center, Yves Chalandon, 215254
PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA AND MLL REARRANGEMENT SHOW A DISTINCTIVE EXPRESSION PATTERN OF HISTONE DEACETYLASES
EHA Learning Center, Nerea Vega-Garcia, 215255
PROTEOLYTIC L-ASPARAGINASE DEGRADATION AS A MECHANISM FOR NON-ANTIBODY-RELATED DRUG INACTIVATION
EHA Learning Center, Justyna Walenciak, 215256
EXTRAMEDULLARY LATE RELAPSES IN ATYPICAL SITES OF ACUTE LYMPHOBLASTIC LEUKEMIA: A RETROSPECTIVE STUDY OF THE ITALIAN ASSOCIATION OF PEDIATRIC HEMATOLOGY AND ONCOLOGY (AIEOP)
EHA Learning Center, Giovanna Giagnuolo, 215257
INCIDENCE AND OUTCOME OF RELAPSES IN YOUNG ADULTS (18-60 YR) WITH PH--POSITIVE ALLTREATED WITH IMATINIB, CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (PETHEMA ALLPH08 TRIAL)
EHA Learning Center, Josep-Maria Ribera, 215258
VENETOCLAX AND NAVITOCLAX WITH CHEMOTHERAPY IS EFFICACIOUS IN PATIENTS WITH RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Thomas Alexander, 215259
IDENTIFICATION OF BCR-ABL-LIKE PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY REAL-TIME PCR
EHA Learning Center, Grigory Tsaur, 215260
DELIVERY OF INTRATHECAL METHOTREXATE CHEMOPROPHYLAXIS TO ADULTS AND TYA PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA – AN AUDIT OF FACTORS AFFECTING PROTOCOL ADHERENCE
EHA Learning Center, Sven Armin Sommerfeld, 215261
THE PROGNOSIS FOR PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WHO WERE INELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN THE TKI ERA.
EHA Learning Center, Akio Shigematsu, 215262
ENHANCING MANAGEMENT OF PH+ ALL BY MONITORING WITH AN ANALYTICALLY VALIDATED MULTIPLEX ASSAY FOR BCR-ABL1 MINOR BREAKPOINT (E1A2) WITH HIGHLY SENSITIVE DETECTION OF 1:40,000 (0.0025% OR 4.6 LOGS)
EHA Learning Center, Justin Brown, 215264
THE RISK OF DEVELOPING HEPATIC TOXICITY FROM PEGYLATED-ASPARAGINASE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS HIGHLY AFFECTED BY CONCOMITANT MEDICATIONS
EHA Learning Center, Paola Minetto, 215265

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings